>
Switch to:

Antares Pharma Operating Income

: $24.1 Mil (TTM As of Jun. 2021)
View and export this data going back to 1996. Start your Free Trial

Antares Pharma's Operating Income for the three months ended in Jun. 2021 was $6.8 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Jun. 2021 was $24.1 Mil.

Operating Margin % is calculated as Operating Income divided by its Revenue. Antares Pharma's Operating Income for the three months ended in Jun. 2021 was $6.8 Mil. Antares Pharma's Revenue for the three months ended in Jun. 2021 was $45.0 Mil. Therefore, Antares Pharma's Operating Margin % for the quarter that ended in Jun. 2021 was 15.09%.

Antares Pharma's 5-Year average Growth Rate for Operating Margin % was 0.00% per year.

Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Antares Pharma's annualized ROC % for the quarter that ended in Jun. 2021 was 27.08%. Antares Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 was 49.00%.


Antares Pharma Operating Income Historical Data

The historical data trend for Antares Pharma's Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Antares Pharma Annual Data
Trend Dec11 Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Operating Income
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -24.12 -16.45 -16.60 0.99 13.62

Antares Pharma Quarterly Data
Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21
Operating Income Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.04 5.85 6.10 5.39 6.79

Antares Pharma Operating Income Calculation

Operating Income, is the profit a company earned through operations. All expenses, including cash expenses such as cost of goods sold (COGS), research & development, wages, and non-cash expenses, such as depreciation, depletion and amortization, have been deducted from the sales.

Operating Income for the trailing twelve months (TTM) ended in Jun. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $24.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Antares Pharma  (NAS:ATRS) Operating Income Explanation

1. Operating Income or EBIT is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Antares Pharma's annualized ROC % for the quarter that ended in Jun. 2021 is calculated as:

ROC % (Q: Jun. 2021 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Mar. 2021 ) + Invested Capital (Q: Jun. 2021 ))/ count )
=27.148 * ( 1 - -20.55% )/( (119.668 + 122.041)/ 2 )
=32.726914/120.8545
=27.08 %

where

Note: The Operating Income data used here is four times the quarterly (Jun. 2021) data.

2. Joel Greenblatt's definition of Return on Capital:

Antares Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Jun. 2021 is calculated as:

ROC (Joel Greenblatt) %(Q: Jun. 2021 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Mar. 2021  Q: Jun. 2021
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=26.792/( ( (28.561 + max(22.199, 0)) + (29.604 + max(28.985, 0)) )/ 2 )
=26.792/( ( 50.76 + 58.589 )/ 2 )
=26.792/54.6745
=49.00 %

where Working Capital is:

Working Capital(Q: Mar. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(42.94 + 19.614 + 4.352) - (43.137 + 1.57 + 1.4210854715202E-14)
=22.199

Working Capital(Q: Jun. 2021 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(54.224 + 18.644 + 4.244) - (45.452 + 2.675 + 0)
=28.985

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Jun. 2021) EBIT data.

3. Operating Income is also linked to Operating Margin %:

Antares Pharma's Operating Margin % for the quarter that ended in Jun. 2021 is calculated as:

Operating Margin %=Operating Income (Q: Jun. 2021 )/Revenue (Q: Jun. 2021 )
=6.787/44.978
=15.09 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

4. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Operating Income growth rate using Operating Income per share data.


Be Aware

Compared with a company's EBITDA margin, Operating Margin can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin may decline. Often the Operating Margin declines well before the company's revenue or even profit decline. Therefore, Operating Margin is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia's Operating Margin had already been in decline since 2002, although its earnings per share were still rising. Investors who paid attention to Operating Margin would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Antares Pharma Operating Income Related Terms

Thank you for viewing the detailed overview of Antares Pharma's Operating Income provided by GuruFocus.com. Please click on the following links to see related term pages.


Antares Pharma Business Description

Antares Pharma logo
Industry
Traded in Other Exchanges
Address
100 Princeton South, Suite 300, Ewing, NJ, USA, 08628
Antares Pharma Inc is a specialty pharmaceutical company. It is focused on the development and commercialization of self-administered parenteral pharmaceutical products and technologies. The company's products include OTREXUP, Elestrin, Gelnique, Makena, and others.
Executives
Greenleaf Peter director ONE MEDIMMUNE WAY GAITHERSBURG MD 20878
Smith Karen L. director C/O JAZZ PHARMACEUTICALS PLC 5TH FL, WATERLOO EXCHANGE, WATERLOO RD DUBLIN L2 4 L2
Powell Fred M officer: Executive Vice President & CFO C/O BEJING MED-PHARM CORPORATION 600 W. GERMANTOWN PIKE, SUITE 400 PLYMOUTH MEETING PA 19462
Garrity Thomas J director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: GARRITY THOMAS J a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Roche Robert P Jr director 41 MOORES ROAD FRAZER PA 19355
Apple Robert F director, officer: President & CEO C/O INKLINE PHARMACEUTICAL CO INC SENTRY PARK EAST 1720 WALTON ROAD BLUE BELL PA 19422
Jacob Leonard S director C/O INKINE PHARMACEUTICAL COMPANY INC 425 PARK AVENUE NEW YORK NY 10022
Graham Peter J officer: EVP General Counsel, Secretary 315 E. 72ND ST. APT 5E NEW YORK NY 10021
Gueth Anton director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: GUETH ANTON a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Samson Marvin director PUBLIC "-//W3C//DTD HTML 4.0 Transitional//EN"> Ownership Information: SAMSON MARVIN a.header:link {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:visited {color: #3b4fae; font-weight: bold; text-decoration: underline;} a.header:hover {color: #191970;}
Tursi James Patrick officer: EVP, Chief Medical Officer 400 ALEXANDER PARK DRIVE PRINCETON NJ 08540
Gonella Jacques director C/O ANTARES PHARMA INC 707 EAGLEVIEW BLVD SUITE 414 EXTON PA 19341
Muckenhirn Keith E officer: VP/Controller & Interim CFO C/O ANTARES PHARMA, INC. 3905 ANNAPOLIS LANE N, SUITE 105 PLYMOUTH MN 55447
Fickenscher James E officer: Senior Vice President & CFO C/O AUXILIUM PHARMACEUTICALS, INC. 640 LEE ROAD CHESTERBROOK PA 19087
Deerfield Special Situations Fund, L.p. 10 percent owner, other: Possible Member of 10% Group 780 3RD AVENUE 37TH FLOOR NEW YORK NY 10017

Antares Pharma Headlines

Other Sources

3 Top Stocks Under $5

By Fool 2020-11-28

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)